Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. (Vaccine, 2007)

(untitled) - Peters, B; Jaoko, W; Vardas, E; Panayotakopoulos, G; Fast, P; Schmidt, C; Gilmour, J; Bogoshi, M; Omosa-Manyonyi, G; Dally, L; Klavinskis, L; Farah, B; et al.